These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28836180)

  • 1. Effect of Liraglutide on Type B Insulin Resistance Syndrome and Insulin Allergy in Type 2 Diabetes: A Case Report.
    Matsumoto Y; Yamada H; Funazaki S; Suzuki D; Kakei M; Hara K
    Diabetes Ther; 2017 Oct; 8(5):1191-1194. PubMed ID: 28836180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of liraglutide on both hypereosinophilic insulin allergy and the characteristics of anti-insulin antibodies in type 2 diabetes mellitus: a case report.
    Hirai H; Ogata E; Kikuchi N; Kohno T; Machii N; Hasegawa K; Watanabe T; Satoh H
    J Med Case Rep; 2016 Jul; 10():202. PubMed ID: 27456688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GLP1 Receptor Agonist Liraglutide Is an Effective Therapeutic Option for Perioperative Glycemic Control in Type 2 Diabetes within Enhanced Recovery After Surgery (ERAS) Protocols.
    Kaneko S; Ueda Y; Tahara Y
    Eur Surg Res; 2018; 59(5-6):349-360. PubMed ID: 30537714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful control of a case of severe insulin allergy with liraglutide.
    Kawanami D; Ito T; Watanabe Y; Kinoshita J; Sakamoto M; Isaka T; Utsunomiya K
    J Diabetes Investig; 2013 Jan; 4(1):94-6. PubMed ID: 24843637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial.
    Ilkowitz JT; Katikaneni R; Cantwell M; Ramchandani N; Heptulla RA
    J Diabetes Sci Technol; 2016 Sep; 10(5):1108-14. PubMed ID: 27184690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide for treating type 1 diabetes.
    Dejgaard TF; Frandsen CS; Holst JJ; Madsbad S
    Expert Opin Biol Ther; 2016; 16(4):579-90. PubMed ID: 26926662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.
    Buse JB; Garber A; Rosenstock J; Schmidt WE; Brett JH; Videbæk N; Holst J; Nauck M
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1695-702. PubMed ID: 21450987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
    Degn KB; Juhl CB; Sturis J; Jakobsen G; Brock B; Chandramouli V; Rungby J; Landau BR; Schmitz O
    Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs.
    Oda H; Mori A; Lee P; Saeki K; Ishioka K; Arai T; Sako T
    Res Vet Sci; 2013 Oct; 95(2):381-8. PubMed ID: 23632200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide 1 receptor agonist ameliorates the insulin resistance function of islet β cells via the activation of PDX-1/JAK signaling transduction in C57/BL6 mice with high-fat diet-induced diabetes.
    Hao T; Zhang H; Li S; Tian H
    Int J Mol Med; 2017 Apr; 39(4):1029-1036. PubMed ID: 28290604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition.
    Streckel E; Braun-Reichhart C; Herbach N; Dahlhoff M; Kessler B; Blutke A; Bähr A; Übel N; Eddicks M; Ritzmann M; Krebs S; Göke B; Blum H; Wanke R; Wolf E; Renner S
    J Transl Med; 2015 Feb; 13():73. PubMed ID: 25890210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus.
    Bruinstroop E; Meyer L; Brouwer CB; van Rooijen DE; van Dam PS
    Diabetes Ther; 2018 Jun; 9(3):1369-1375. PubMed ID: 29779196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
    Rendell M
    Drugs Today (Barc); 2015 Mar; 51(3):185-96. PubMed ID: 25876562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin degludec + liraglutide: a complementary combination.
    Stinkens K; Peene B; Mathieu C
    Expert Opin Biol Ther; 2016 Sep; 16(9):1171-7. PubMed ID: 27484310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three years of liraglutide treatment offers continuously optimal glycemic control in a pediatric patient with maturity-onset diabetes of the young type 3.
    Urakami T; Habu M; Okuno M; Suzuki J; Takahashi S; Yorifuji T
    J Pediatr Endocrinol Metab; 2015 Mar; 28(3-4):327-31. PubMed ID: 25332292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
    Díaz-Soto G; de Luis DA; Conde-Vicente R; Izaola-Jauregui O; Ramos C; Romero E
    Diabetes Res Clin Pract; 2014 Apr; 104(1):92-6. PubMed ID: 24530118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
    Guyton J; Jeon M; Brooks A
    Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2014 Dec; 74(18):2161-74. PubMed ID: 25367717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
    Vedtofte L; Knop FK; Vilsbøll T
    Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Diabetes Mellitus With Glucagonlike Peptide-1 Agonist Liraglutide in Renal Transplant Recipients: A Retrospective Study.
    Liou JH; Liu YM; Chen CH
    Transplant Proc; 2018 Oct; 50(8):2502-2505. PubMed ID: 30316386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.